Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIT in advanced breast cancer
NCT03202446Phase 3Terminated
- Sponsor
- ESKE Group
- Start
- Jun 2016
- Primary completion
- Jan 2018
- Modality
- Polymer-based Nanoparticles
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of glycated chitosan in breast cancer (3 arms), sponsored by ESKE Group. Primary endpoint: Overall Response Rate at 52 weeks. Started Jun 2016; status: terminated.
02
Drugs
glycated chitosan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03202446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03202446.